Allurion Technologies: Allurion Program safe and effective in adolescents

Allurion Technologies announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents… Task Force concluded that the evidence for the use of pharmacotherapy-including GLP-1 drugs-was inadequate in children and adolescents…. This study affirms Allurion’s belief that the Allurion Balloon represents a novel, non-invasive, safe, and effective treatment option for adolescents which can allow for earlier intervention in the treatment of obesity. “Bariatric surgery and long-term pharmacotherapy, although effective in adults, raises concerns about invasiveness and potential risks when applied to adolescents,” said Dr. Ram Chuttani, Chief Medical Officer of Allurion. “We believe that the results of this study mark a significant milestone in the treatment of adolescent obesity, as the Allurion Balloon offers a non-invasive treatment option without several of the issues related to surgery and medications.”